Skip to content
Subscriber Only

Express Scripts Sells Unit With Ties to a $35,000-a-Vial Drug

  • Investor Jim Chanos has said he’s shorting companies’ stocks
  • Private equity firm Avista to buy United BioSource unit
1501706235_GettyImages-120306978

Photographer: Bloomberg

Updated on

Express Scripts Holding Co. is trimming some of its ties to a $35,000-a-vial medicine made by Mallinckrodt Plc by selling a unit that helps patients access some high-priced drugs.

Avista Capital Partners, a private equity firm, will buy Express Scripts’ United BioSource division, the firms said in a statement. United BioSource’s website says it helps “maximize product access and commercialization,” helps drug companies “overcome access and adherence challenges” and provides drug testing services.